STERIS (NYSE:STE) Issues FY 2026 Earnings Guidance

Key Points

• STERIS (NYSE:STE) has issued earnings per share guidance for FY 2026 in the range of 9.900-10.150, slightly below the consensus estimate of 10.046.
• Wall Street analysts appear optimistic about STERIS, with several upgrades and price target increases, reflecting a consensus rating of "Moderate Buy" and an average price target of $270.33.
• The company recently announced an increase in its quarterly dividend to $0.63, boosting the annualized dividend to $2.52 and representing a yield of 1.1%.

STERIS (NYSE:STE - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 9.900-10.150 for the period, compared to the consensus earnings per share estimate of 10.046. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STE. Morgan Stanley raised shares of STERIS from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $260.00 to $276.00 in a research note on Tuesday, July 15th. Stephens reaffirmed an "overweight" rating and issued a $250.00 price objective on shares of STERIS in a report on Thursday, May 15th. JMP Securities boosted their target price on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research note on Friday, May 16th. Citigroup reissued an "outperform" rating on shares of STERIS in a research note on Friday, May 16th. Finally, Wall Street Zen lowered STERIS from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $270.33.

STERIS Stock Performance

NYSE:STE traded up $14.00 during trading hours on Thursday, reaching $235.21. The company had a trading volume of 531,423 shares, compared to its average volume of 601,820. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39. The firm has a market cap of $23.14 billion, a PE ratio of 38.10 and a beta of 0.92. The business's 50 day moving average price is $234.35 and its 200-day moving average price is $228.30. STERIS has a 1-year low of $200.98 and a 1-year high of $252.79.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.02. The firm had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. STERIS had a net margin of 11.26% and a return on equity of 14.21%. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.03 EPS. Research analysts forecast that STERIS will post 9.08 EPS for the current year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 26th. Investors of record on Thursday, September 4th will be issued a $0.63 dividend. This is a boost from STERIS's previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, September 4th. STERIS's dividend payout ratio is currently 36.77%.

Insiders Place Their Bets

In related news, CEO Daniel A. Carestio sold 17,626 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $242.56, for a total value of $4,275,362.56. Following the completion of the transaction, the chief executive officer owned 51,385 shares of the company's stock, valued at approximately $12,463,945.60. This trade represents a 25.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Cary L. Majors sold 12,828 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the sale, the senior vice president directly owned 11,372 shares of the company's stock, valued at $2,843,909.76. The trade was a 53.01% decrease in their position. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

Several institutional investors and hedge funds have recently modified their holdings of STE. Jones Financial Companies Lllp grew its stake in shares of STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider's stock worth $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. increased its position in STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider's stock worth $55,015,000 after purchasing an additional 59,264 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider's stock valued at $522,000 after purchasing an additional 319 shares during the period. Woodline Partners LP lifted its holdings in shares of STERIS by 40.0% during the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider's stock valued at $1,881,000 after purchasing an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider's stock worth $4,695,000 after acquiring an additional 5,803 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.